BioSpace News Archive

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), and Bolt Biotherapeutics, Inc. (“Bolt”) (Nasdaq: BOLT), today announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates.

Patterson Companies announced that it will hold its fiscal 2022 first-quarter conference call on Thursday, September 2, 2021 at 7:30 a.m. CT.

Laekna Therapeutics announced that the Center for Drug Evaluation, the National Medical Products Administration of China has approved the Investigational New Drug application of its Category 1 new drug candidate afuresertib in combination with anti-estrogen receptor drug fulvestrant in the Phase Ib/III clinical trial of patients with locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.